Biotech Valuations con't... and the import of the high # of "shots on goal" with RGBP's 20+ mRNA Patents/NR2F6.
The more shots on goal "the greater the likelihood that their approach will yield a blockbuster product."
From the McKinsey & Company 2020 whitepaper: Delivering innovation: 2020 oncology market outlook
In addition to abundant organic R&D at both large pharmaceutical companies and numerous clinical-stage biotechs, we have observed a spate of multibillion dollar oncology-focused acquisitions (such as Pfizer’s 2019 acquisition of Array BioPharma for $11 billion) and partnerships (including a $3 billion collaboration between AbbVie and Genmab on bispecific antibodies). Excitement about oncology targets has driven high deal premiums. Over the past five years, the median oncology acquisition premium was approximately 100 percent for transactions with a deal value of more than $5 billion.
In the commercial setting, most major pharmaceutical companies are focused on synergistic subsets of indications with overlapping call points and opinion-leader relationships. In the R&D setting, however, beyond their hypotheses, scientists don’t know where a new therapy will work. So we see most players exploring a wider set of indications by taking more “shots on goal”—the more indications they address, the greater the likelihood that their approach will yield a blockbuster product
Market Data 
Markets 
AI
